Relative Potency Factor in Risk Assessment is the EPA’s primary quantitative method for evaluating chemical mixtures with a shared mechanism of toxicity. The Relative Potency Factor in Risk Assessment compares the toxicity of each component to an index chemical, enabling regulators to convert complex mixtures into a single equivalent dose. This guide explains how to apply Relative Potency Factor in Risk Assessment to PFAS, PAHs, and pesticide groups using current EPA and EFSA methodology.
| Key Takeaways |
| The Relative Potency Factor (RPF) is a dimensionless value expressing the toxic potency of a substance relative to an index (reference) compound. The formula is: RPF = Dose of Index Chemical / Dose of Test Chemical that produces the same toxic effect. |
| The EPA uses the RPF approach as its primary methodology for cumulative risk assessment of chemical mixtures that share a common mechanism of toxicity, mandated under the 1996 Food Quality Protection Act (FQPA) and Safe Drinking Water Act Amendments. |
| The RPF approach has been applied to major regulatory programs: organophosphate pesticides (31 chemicals assessed cumulatively), polycyclic aromatic hydrocarbons (PAHs, with benzo[a]pyrene as the index compound), and most recently PFAS (per- and polyfluoroalkyl substances, with PFOA as the index compound in the EPA 2024 PFAS mixtures framework). |
| RPF differs from the related Toxic Equivalency Factor (TEF) approach: TEF values are consensus-based and internationally harmonized (primarily for dioxins and PCBs), while RPFs are derived from available dose-response data and may be chemical-group specific with more flexibility in application. |
| The EPA’s 2024 Final Framework for Estimating Noncancer Health Risks Associated with Mixtures of PFAS established RPF as one of three component-based approaches (alongside the Hazard Index and Mixture Benchmark Dose methods) for assessing PFAS mixture risk. |
| Limitations include the assumption of dose additivity and similar dose-response curve shapes, data gaps for many chemicals, and challenges in extrapolating across species and exposure routes. Practitioners must document assumptions and uncertainties when applying RPF in regulatory or enterprise risk contexts. |
The U.S. Environmental Protection Agency’s 2024 Final Framework for PFAS mixture risk assessment established the Relative Potency Factor as one of three primary approaches for evaluating the combined health risks of per- and polyfluoroalkyl substances in drinking water (EPA-815-R-24-003).
This framework applied RPFs to 22 PFAS compounds relative to the index chemical PFOA, enabling regulators to express complex mixture exposures as a single equivalent concentration that can be compared against established health-based guidance values.
The RPF approach is not new — the EPA has used it for cumulative risk assessment of organophosphate pesticides since the early 2000s — but its extension to PFAS represents the most significant recent regulatory application of this methodology.
The Relative Potency Factor is a quantitative tool for comparing the toxic potency of different substances that produce toxicity through the same or similar biological mechanisms.
This article explains what the RPF is, how it is calculated, where it is used in regulatory decision-making, and how it connects to broader risk assessment and risk management frameworks.
The focus is on practical understanding for risk professionals who encounter RPF in environmental, occupational, or product safety contexts.
What the Relative Potency Factor Actually Is
The Relative Potency Factor is a dimensionless ratio that expresses the toxic potency of one substance relative to a designated reference compound (the index chemical).
The RPF quantifies how much more or less potent a substance is compared to the index chemical in producing a specific toxic effect.
The index chemical’s RPF is, by definition, 1.0.
All other chemicals in the group are expressed as fractions or multiples of the index chemical’s potency.
The formula is straightforward: RPF = Dose of Index Chemical that produces a defined effect / Dose of Test Chemical that produces the same effect.
A chemical with an RPF of 2.0 is twice as potent as the index chemical (it takes half the dose to produce the same toxic effect).
A chemical with an RPF of 0.1 is one-tenth as potent (it takes 10 times the dose to produce the same effect).
This simple ratio enables complex mixtures of multiple chemicals to be converted into a single equivalent dose of the index chemical, which can then be compared against an established health-based guidance value.
RPF Terminology and Definitions
| Term | Definition | Practical Significance |
| Relative Potency Factor (RPF) | Dimensionless ratio comparing the toxic potency of a test chemical to an index chemical for a specific toxic endpoint | Enables conversion of mixture exposures into index chemical equivalents for comparison against health guidance values |
| Index Chemical | The reference compound to which all other chemicals in the group are compared; its RPF is defined as 1.0 | Should have the highest-quality dose-response data, be representative of the common toxic mechanism, and be well-characterized toxicologically |
| Cumulative Assessment Group (CAG) | The group of chemicals selected for cumulative risk assessment based on sharing a common mechanism of toxicity | Defines the boundary of which chemicals are included in the RPF-based assessment; membership is determined by mechanistic evidence |
| Common Mechanism of Toxicity | Two or more chemicals that cause a common toxic effect by the same sequence of biochemical events | The fundamental prerequisite for applying the RPF approach; chemicals must act through the same biological pathway |
| Dose Addition | The assumption that chemicals in a mixture contribute to the total effect in proportion to their individual doses, adjusted by their relative potency | The mathematical basis for the RPF approach; assumes that mixture components can be treated as dilutions or concentrations of the index chemical |
| Index Chemical Equivalent Concentration (ICEC) | The measured concentration of a chemical in a mixture multiplied by its RPF, converting it to an equivalent concentration of the index chemical | The operational output of the RPF calculation; ICECs are summed across all mixture components to produce a total equivalent exposure |
How RPF Is Calculated for Relative Potency Factor in Risk Assessment
RPF calculation requires dose-response data for both the index chemical and each test chemical within the cumulative assessment group.
The process involves selecting a common toxic endpoint, fitting dose-response models to the data, and deriving the potency ratio at equivalent effect levels.
The EPA’s Guidance on Cumulative Risk Assessment of Pesticide Chemicals provides the authoritative methodology.
RPF Calculation Steps
| Step | Actions | Data Requirements | Output |
| 1. Define the CAG | Identify chemicals sharing a common mechanism of toxicity based on mechanistic and toxicological evidence | Mode-of-action studies; structure-activity relationships; common effect endpoint identification | List of chemicals in the cumulative assessment group with documented mechanistic basis |
| 2. Select the index chemical | Choose a well-characterized reference compound with high-quality dose-response data representative of the common toxic effect | Extensive dose-response database for the selected endpoint; well-understood mechanism; available data across relevant exposure routes | Designated index chemical with RPF = 1.0 |
| 3. Identify the common endpoint | Select the toxic endpoint that best represents the common mechanism across all CAG members | Toxicity study data for each chemical; endpoint concordance across the group; route-specific data (oral, dermal, inhalation) | Defined endpoint (e.g., acetylcholinesterase inhibition for organophosphates; liver weight increase for PFAS) |
| 4. Derive dose-response data | Extract NOAEL, LOAEL, or benchmark dose (BMD) values for each chemical at the common endpoint | Individual chemical toxicity studies; dose-response modeling results; species and sex-specific data | Point of departure (POD) for each chemical in the CAG |
| 5. Calculate RPFs | Divide the index chemical’s POD by each test chemical’s POD: RPF = POD(index) / POD(test chemical) | PODs for all chemicals at the common endpoint; consistent study design and species where possible | RPF value for each chemical in the CAG (index chemical = 1.0) |
| 6. Apply to exposure data | Multiply measured concentrations of each chemical by its RPF to convert to index chemical equivalent concentrations; sum all ICECs | Environmental monitoring data or exposure estimates for each chemical in the mixture | Total Index Chemical Equivalent Concentration (Total ICEC) for comparison against health guidance values |
Major Regulatory Applications of Relative Potency Factor in Risk Assessment
The RPF approach has been applied to three major chemical groups in U.S. and international regulatory programs, each representing a different type of environmental and health risk challenge.
RPF Applications Across Chemical Groups
| Chemical Group | Index Chemical | Common Mechanism / Endpoint | Number of Chemicals Assessed | Regulatory Context |
| Organophosphate pesticides | Methamidophos | Acetylcholinesterase (AChE) inhibition in the nervous system | 31 pesticides in the CAG | EPA cumulative risk assessment under FQPA (1996); RPFs derived for oral, dermal, and inhalation routes |
| Polycyclic aromatic hydrocarbons (PAHs) | Benzo[a]pyrene (BaP) | Genotoxic carcinogenicity via DNA adduct formation | 34 PAHs assessed for carcinogenic potency relative to BaP | EPA IRIS draft RPF approach (2010, suspended); widely used in contaminated site risk assessment |
| PFAS (per- and polyfluoroalkyl substances) | PFOA (perfluorooctanoic acid) | Multiple endpoints including liver effects and immunotoxicity | 22 PFAS with RPFs derived (2021 study); EPA 2024 framework applies RPF as one of three approaches | EPA 2024 Final Framework (EPA-815-R-24-003); EFSA 2020 assessment used equal potency for 4 PFAS |
| Dioxins and dioxin-like compounds | 2,3,7,8-TCDD | AhR-mediated toxicity | 29 congeners with WHO-established TEFs (related but distinct from RPF) | WHO TEF scheme (1998, updated 2005); EPA and ECHA guidance; TEFs are consensus-based vs. data-derived RPFs |
| N-methyl carbamate pesticides | Oxamyl | Acetylcholinesterase (AChE) inhibition (reversible) | 11 carbamate pesticides | EPA cumulative risk assessment under FQPA; separate from organophosphate CAG due to reversible vs. irreversible AChE inhibition |
RPF vs. TEF: Understanding the Difference
Practitioners frequently encounter both Relative Potency Factors (RPFs) and Toxic Equivalency Factors (TEFs) in regulatory risk assessment.
While both express relative toxicity, they differ in derivation, governance, and application.
Understanding the distinction is important for applying the correct methodology in the correct regulatory context.
RPF vs. TEF Comparison
| Dimension | Relative Potency Factor (RPF) | Toxic Equivalency Factor (TEF) |
| Derivation | Data-driven: derived from available dose-response studies for each chemical relative to the index compound | Consensus-based: established through expert panels (WHO) using weight-of-evidence review across multiple data types |
| Governance | Agency-specific: EPA, EFSA, and other regulators may derive RPFs independently based on available data | Internationally harmonized: WHO convenes expert panels to establish TEF values that are used globally |
| Chemical scope | Flexible: can be applied to any group of chemicals sharing a common mechanism of toxicity | Narrow: primarily established for dioxins, furans, and dioxin-like PCBs (29 congeners in the WHO TEF scheme) |
| Update frequency | Can be updated as new data become available; no formal consensus process required | Updated periodically through WHO expert consultations (1998, 2005); revisions are infrequent |
| Assumption | Dose addition with parallel dose-response curves (same slope assumption) | Dose addition; TEF values represent a broader range of toxic endpoints (not limited to a single mechanism) |
| Primary use | Cumulative risk assessment of pesticides, PAHs, PFAS; contaminated site risk assessment | Dioxin and PCB risk assessment; regulatory limit setting; food safety standards |
Connecting Relative Potency Factor in Risk Assessment to Enterprise Risk Management
While the RPF is a specialized toxicological tool, its principles connect directly to the quantitative risk assessment approaches used in enterprise risk management.
The RPF demonstrates a broader principle: when multiple hazards act through similar pathways, their combined effect can be estimated by normalizing each hazard to a common reference and summing the contributions.
This dose-addition logic applies to financial risk aggregation, operational risk accumulation, and any context where multiple risk sources compound through a shared mechanism.
RPF–ERM Conceptual Parallels
| RPF Concept | ERM Parallel | Application in Enterprise Risk | Framework Reference |
| Index chemical (reference compound) | Risk appetite baseline (the threshold against which all risks are measured) | Expressing all risks in common units (financial impact equivalent) relative to a defined baseline tolerance | ISO 31000 risk criteria; COSO ERM risk appetite |
| Relative potency factor (ratio to index) | Risk weighting factor (severity multiplier for different risk categories) | Weighting operational, financial, cyber, and compliance risks by their relative impact potential to produce a comparable risk profile | Risk assessment matrix; weighted risk scoring models |
| Cumulative assessment (sum of ICECs) | Portfolio risk aggregation (sum of weighted risk exposures across categories) | Aggregating individual risks into a total enterprise risk exposure figure for comparison against organizational risk capacity | COSO ERM portfolio view; ISO 31000 risk evaluation |
| Common mechanism of toxicity | Common risk driver (shared causal pathway through which multiple risks materialize) | Identifying when multiple risks share root causes (e.g., supply chain dependency, technology failure, regulatory change) and assessing their combined effect | Bow-tie analysis; risk interdependency mapping |
| Dose addition assumption | Risk additivity assumption (individual risk contributions sum to total exposure) | Assuming that individual risk exposures aggregate proportionally; recognizing when correlation or interaction effects may amplify or dampen the total | Monte Carlo simulation; correlation-adjusted VaR |
The quantitative risk assessment methods used in ERM (Monte Carlo simulation, sensitivity analysis, scenario analysis) address a similar challenge to what the RPF solves in toxicology: how do you combine multiple sources of risk into a single, actionable assessment that decision-makers can use to allocate resources?
The RPF’s normalized ratio approach is one answer; portfolio risk aggregation models are another.
Understanding both strengthens a practitioner’s ability to communicate and manage risk across domains.
Limitations and Best Practices for Relative Potency Factor in Risk Assessment
The RPF approach is powerful but not without constraints. Practitioners must understand and document these limitations when applying RPF in regulatory submissions or risk assessments, following the same transparency principles required under ISO 31000 for documenting risk assessment assumptions and uncertainties.
Limitations and How to Address Them
| Limitation | Why It Matters | Mitigation Approach |
| Assumes dose addition and parallel dose-response curves | The RPF method requires that all chemicals in the CAG produce toxicity through the same mechanism and have similar-shaped dose-response curves; if slopes differ significantly, the RPF may over- or underestimate combined risk | Use statistical clustering methods (as proposed by EPA) to group chemicals with truly parallel slopes; apply the Hazard Index method as a complementary approach when slope parallelism cannot be confirmed |
| Data gaps for many chemicals | RPF calculation requires dose-response data at the common endpoint for each chemical; for some chemicals, adequate data may not exist, particularly for emerging contaminants | Use read-across from structurally similar chemicals with available data; apply conservative default RPFs where specific data are unavailable; document all data gap assumptions transparently |
| Species and route extrapolation | RPFs derived from animal studies must be extrapolated to human risk; data may exist for different species, strains, or exposure routes for different chemicals in the CAG | Use consistent species/strain/sex data across the CAG where possible; apply uncertainty factors for interspecies extrapolation; document all extrapolation assumptions |
| Sensitivity to index chemical selection | Different index chemicals can produce different RPF values and different predicted mixture risks | Select the index chemical with the most robust dose-response data and the most representative toxicological profile; conduct sensitivity analysis using alternative index chemicals |
| Does not account for non-additive interactions | The dose addition model does not capture synergistic (greater than additive) or antagonistic (less than additive) interactions between mixture components | Document the dose addition assumption; where data suggest non-additive interactions, apply interaction-based models or add safety factors to the assessment |
| Endpoint-specific values | RPFs are derived for specific toxic endpoints and may not apply across all health effects caused by the same chemical group | Derive RPFs for the most health-protective endpoint; consider separate RPF sets for different endpoints where the regulatory context requires it |
Implementation Roadmap for Relative Potency Factor in Risk Assessment
| Phase | Actions | Deliverables | Success Metrics |
| Days 1–30: Foundation | Identify chemical groups within your operations or products requiring cumulative risk assessment; review applicable regulatory guidance (EPA, EFSA, ECHA); assemble toxicological data for candidate chemicals; determine whether RPF, TEF, or Hazard Index is the appropriate methodology | Chemical inventory mapped to potential CAGs; regulatory requirement matrix; data availability assessment per chemical; methodology selection decision documented | All relevant chemical groups identified; regulatory requirements confirmed; data gaps cataloged; methodology justified and documented |
| Days 31–60: Analysis | Define the CAG and select the index chemical; compile dose-response data at the common endpoint; calculate RPFs for each chemical; apply RPFs to exposure data to derive total ICEC; compare total ICEC against health-based guidance values | Calculated RPFs for all chemicals in the CAG; exposure assessment results; total ICEC for each relevant mixture; comparison against health guidance values; sensitivity analysis with alternative index chemicals | RPFs calculated and validated; total mixture risk quantified; results compared against regulatory thresholds; sensitivity analysis completed |
| Days 61–90: Documentation and Integration | Document the complete RPF assessment with all assumptions, data sources, and uncertainty analysis; integrate results into the organization’s risk register; develop risk communication materials for stakeholders; establish monitoring and update schedule | Complete RPF risk assessment report; results integrated into enterprise risk register; stakeholder communication materials; annual review schedule; action plan for any exceedances identified | Assessment report passes regulatory review criteria; risk register updated; stakeholders informed; monitoring and update cadence established |
Common Pitfalls in Relative Potency Factor in Risk Assessment and How to Avoid Them
| Pitfall | Root Cause | Remedy |
| Applying RPF to chemicals that do not share a common mechanism | Grouping chemicals by structural similarity rather than demonstrated mechanistic commonality | Require mechanistic evidence (mode of action studies, structure-activity data) before including a chemical in a CAG; do not use RPF as a default for all chemical mixtures |
| Using RPF values from one endpoint to assess risk for a different health effect | RPFs are endpoint-specific; a chemical’s relative potency for liver toxicity may differ substantially from its relative potency for immunotoxicity | Derive or select RPFs specific to the health endpoint being assessed; use the most health-protective endpoint when multiple endpoints are relevant |
| Treating RPF as a fixed constant rather than a value with uncertainty | RPFs are estimates derived from limited data with inherent variability; treating them as precise values creates false confidence | Report RPF values with confidence intervals where data permit; conduct sensitivity analysis showing how uncertainty in RPFs affects the total mixture risk estimate |
| Ignoring exposure route differences | RPFs may differ across oral, dermal, and inhalation routes of exposure due to differences in absorption and metabolism | Derive route-specific RPFs where data are available; do not apply oral RPFs to inhalation exposure scenarios without documented justification |
| Failing to update RPFs as new data become available | Initial RPF values treated as permanent; no process for incorporating new toxicological studies | Establish a periodic review cycle (at least every 3 years) to evaluate whether new data warrant RPF updates; monitor regulatory agency RPF revisions |
| Not documenting the dose addition assumption | Regulators and auditors require transparency about the mathematical basis of the assessment; undocumented assumptions create compliance risk | Explicitly state the dose addition assumption in every RPF assessment report; document the mechanistic basis supporting the assumption; note where non-additive interactions are possible |
FAQ Section: Relative Potency Factor in Risk Assessment
What is a relative potency factor in risk assessment, in plain English?
It is a dimensionless ratio that says how toxic one chemical is compared with a chosen reference compound for the same health effect. If the reference has an RPF of 1.0, a chemical with an RPF of 0.5 is half as potent and one with 2.0 is twice as potent.
The EPA’s cumulative risk assessment guidance uses this ratio to compare apples to apples inside a chemical mixture.
How do you calculate a relative potency factor in risk assessment?
Pick the index chemical, identify a common toxic endpoint, extract a point of departure (NOAEL, LOAEL, or benchmark dose) for each chemical, then divide the index POD by each test chemical’s POD. That ratio is the RPF.
The EPA’s RPF technical guidance walks through the math step by step. Document every dose-response curve and uncertainty factor so reviewers can reproduce the number.
What’s the difference between a relative potency factor and a toxic equivalency factor (TEF)?
RPFs are data-driven and agency-specific — the EPA derives them from dose-response studies for whatever group it is regulating. TEFs are consensus values published by WHO expert panels, almost exclusively for dioxins, furans, and dioxin-like PCBs.
The US EPA dioxin reassessment still uses WHO TEFs, while pesticide and PFAS programs use RPFs. Both rely on the dose-addition assumption underneath.
How does the EPA use the relative potency factor in risk assessment for PFAS under the 2024 Framework?
The EPA’s 2024 Final Framework for PFAS Mixtures (EPA-815-R-24-003) names the RPF approach as one of three component-based methods, alongside the Hazard Index and Mixture Benchmark Dose. PFOA is the index chemical.
Drinking water and contaminated-site assessments multiply each PFAS concentration by its RPF, sum them, then compare the total to PFOA-based health guidance values.
Can a relative potency factor in risk assessment be applied to chemicals that do not share a common mechanism of toxicity?
No. Common mechanism of toxicity is a hard prerequisite — the chemicals must produce the same toxic effect by the same biochemical pathway. Applying RPFs across mechanisms produces a number, but not a defensible one.
The EPA’s guidance on common mechanism groups sets the criteria. Use the Hazard Index instead when chemicals affect different organ systems or use unrelated mechanisms.
What is the index chemical in a relative potency factor risk assessment, and how is it chosen?
The index chemical is the reference compound whose RPF is fixed at 1.0; every other chemical’s potency is measured against it.
Selection requires the most robust dose-response data, well-characterized toxicology, and a documented mode of action.
Common index chemicals include benzo[a]pyrene for PAHs, methamidophos for organophosphates, and PFOA for PFAS in the EPA’s 2024 framework. Document the rationale; auditors check this first.
How does the relative potency factor in risk assessment connect to enterprise risk management?
RPF logic translates cleanly into ERM: the index chemical maps to a risk appetite baseline, RPFs to risk weighting factors, and the summed ICEC to portfolio risk aggregation.
The COSO ERM Framework treats this kind of weighted aggregation as the connective tissue between operational, financial, and compliance risk.
EHS managers increasingly feed RPF-based regulatory findings into the enterprise risk register and board-level dashboards.
How often should relative potency factors in risk assessment be updated as new toxicology data emerge?
At minimum every three years, and immediately when a new mode-of-action study, an EPA reassessment, or a high-throughput screening dataset materially changes the dose-response curve.
The EPA IRIS program updates assessments on a rolling cycle, and the ATSDR toxicological profiles refresh on a similar cadence.
Treating RPFs as fixed constants is the single most common audit finding in cumulative risk programs.
Looking Ahead: RPF Trends for 2026–2028
The EPA’s 2024 PFAS Mixtures Framework represents the most significant recent expansion of RPF methodology. The framework established RPF as one of three component-based approaches for PFAS mixture risk assessment, alongside the Hazard Index and Mixture Benchmark Dose methods.
This three-method approach provides regulators with flexibility to match the methodology to available data, with the RPF offering the most granular comparison of individual compound potencies.
As PFAS regulation continues to expand globally, RPF-based mixture assessment will become increasingly central to drinking water standards, contaminated site cleanup decisions, and industrial discharge permitting.
New Approach Methodologies (NAMs) are changing how RPFs are derived.
High-throughput screening, in vitro assays, and computational toxicology models are generating potency data for chemicals that lack traditional animal study data, enabling RPF estimation for a much broader set of compounds.
The EPA’s framework explicitly discusses integrating NAM-based RPFs into mixture assessments, signaling a shift toward faster, more data-rich RPF derivation that addresses the chronic challenge of data gaps in cumulative risk assessment.
The convergence of RPF methodology with enterprise risk management principles is accelerating.
Environmental, health, and safety (EHS) risk managers increasingly need to translate RPF-based regulatory findings into enterprise risk register entries, financial exposure estimates, and board-level risk communications.
The same quantitative normalization logic that makes RPF effective in toxicology (expressing diverse risks in common units for comparison) applies to risk quantification for board reporting, where diverse operational, financial, and compliance risks must be expressed in comparable terms to support strategic decision-making.
Practitioners who understand RPF methodology are better equipped to interpret environmental compliance requirements, challenge or validate risk assessments prepared by consultants or regulators, and integrate chemical risk data into their organization’s broader risk management framework.
As chemical mixture regulation becomes more sophisticated, the RPF will remain a foundational tool in the practitioner’s quantitative risk assessment toolkit.
Strengthen your chemical and environmental risk assessment capabilities.
Visit riskpublishing.com for risk assessment frameworks, quantitative analysis guides, and practitioner resources.
Need support? Contact our consulting team for tailored risk management solutions.
References
1. EPA – Final Framework for Estimating Noncancer Health Risks Associated with Mixtures of PFAS (EPA-815-R-24-003, 2024) – Three-method PFAS mixture risk assessment including RPF approach
2. EPA – Guidance on Cumulative Risk Assessment of Pesticide Chemicals That Have a Common Mechanism of Toxicity – Authoritative RPF methodology for pesticide cumulative risk assessment
3. EPA – Developing Relative Potency Factors for Pesticide Mixtures: Biostatistical Analyses of Joint Dose-Response – Statistical methods for RPF derivation under dose addition
4. EPA – Development of a Relative Potency Factor (RPF) Approach for PAH Mixtures (External Review Draft) – PAH mixture RPF methodology with BaP as index compound
5. EPA IRIS – RPF Approach for PAH Mixtures (Suspended Assessment) – Detailed RPF methodology for polycyclic aromatic hydrocarbons
6. EPA – Cumulative Risk Assessment for Quantitative Response Data – Statistical clustering methods for chemicals with differing dose-response slopes
7. PubMed – Risk Assessment of PFAS Mixtures: A Relative Potency Factor Approach (Bil et al., 2021) – RPFs for 22 PFAS relative to PFOA for oral exposure assessment
8. ScienceDirect – Internal Relative Potency Factors for PFAS Based on Immunotoxicity (2023) – Novel internal RPF derivation using NHANES epidemiological data
9. PubMed – Utilizing RPF and TTC Concepts for Environmental Metabolite Risk Assessment – RPF methodology for pesticide metabolite hazard assessment
10. EPA – Overview of Risk Assessment in the Pesticide Program – Context for RPF within EPA’s broader pesticide risk assessment framework
11. WHO – Environmental Health Criteria 239: Principles for Modelling Dose-Response for Risk Assessment of Chemicals – International guidance on dose-response modeling relevant to RPF derivation
12. ECHA – Guidance on Information Requirements and Chemical Safety Assessment – European regulatory framework for chemical risk assessment including mixture approaches
13. EFSA – Risk to Human Health Related to the Presence of PFAS in Food (2020) – EFSA TWI for 4 PFAS based on immunotoxicity with equal potency assumption
14. NumberAnalytics – Relative Potency Factor: A Key to Toxicity Assessment – Overview of RPF definition, regulatory applications, and future directions
15. ISO – ISO 31000:2018 Risk Management Guidelines – Universal risk management framework for integrating chemical risk into enterprise
Chris Ekai is a Risk Management expert with over 10 years of experience in the field. He has a Master’s(MSc) degree in Risk Management from University of Portsmouth and is a CPA and Finance professional. He currently works as a Content Manager at Risk Publishing, writing about Enterprise Risk Management, Business Continuity Management and Project Management.